Total Payments
$483,835
2024 Payments
$37,914
Companies
50
Transactions
1,542
Medicare Patients
7,106
Medicare Billing
$933,350
Payment Breakdown by Category
Other$342,232 (70.7%)
Consulting$60,670 (12.5%)
Travel$50,913 (10.5%)
Food & Beverage$29,722 (6.1%)
Education$297.39 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $342,232 | 120 | 70.7% |
| Consulting Fee | $60,670 | 19 | 12.5% |
| Travel and Lodging | $50,913 | 115 | 10.5% |
| Food and Beverage | $29,722 | 1,278 | 6.1% |
| Education | $297.39 | 10 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $175,532 | 128 | $0 (2024) |
| Gilead Sciences, Inc. | $141,561 | 183 | $0 (2019) |
| ARALEZ PHARMACEUTICALS US INC. | $69,183 | 102 | $0 (2018) |
| Esperion Therapeutics, Inc. | $32,987 | 56 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $22,764 | 177 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $8,306 | 8 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $7,836 | 52 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $6,492 | 30 | $0 (2019) |
| Medtronic, Inc. | $2,889 | 39 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $2,830 | 103 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $37,914 | 120 | Novo Nordisk Inc ($35,418) |
| 2023 | $54,000 | 147 | Novo Nordisk Inc ($47,861) |
| 2022 | $109,617 | 228 | Novo Nordisk Inc ($91,983) |
| 2021 | $28,775 | 192 | Esperion Therapeutics, Inc. ($13,725) |
| 2020 | $15,095 | 182 | Esperion Therapeutics, Inc. ($12,315) |
| 2019 | $9,808 | 170 | Novartis Pharmaceuticals Corporation ($7,181) |
| 2018 | $97,977 | 207 | Gilead Sciences, Inc. ($61,494) |
| 2017 | $130,649 | 296 | Gilead Sciences Inc ($80,046) |
All Payment Transactions
1,542 individual payment records from CMS Open Payments — Page 1 of 62
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $18.45 | General |
| Category: Cardiology | ||||||
| 12/17/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $25.16 | General |
| Category: Obesity | ||||||
| 12/13/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $24.41 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/09/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $20.61 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/09/2024 | Medtronic, Inc. | MYCARELINK (Device) | Food and Beverage | In-kind items and services | $13.60 | General |
| Category: Cardiac Diagnostics and Monitoring | ||||||
| 11/22/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $17.79 | General |
| Category: Diabetes | ||||||
| 11/21/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,938.00 | General |
| Category: Diabetes | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $13.40 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/18/2024 | Abbott Laboratories | CARDIOMEMS (Device) | Food and Beverage | In-kind items and services | $29.69 | General |
| Category: Heart Failure | ||||||
| 11/12/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $18.60 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/08/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $2.26 | General |
| Category: Diabetes | ||||||
| 11/06/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $32.37 | General |
| Category: Cardiology | ||||||
| 11/05/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $18.56 | General |
| Category: Cardio-renal | ||||||
| 10/28/2024 | Chiesi USA, Inc. | CLEVIPREX (Drug), KENGREAL | Food and Beverage | Cash or cash equivalent | $16.45 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/25/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $24.31 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/21/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $26.74 | General |
| Category: Obesity | ||||||
| 10/18/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $13.67 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/16/2024 | ATRICURE, INC. | EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX (Device) | Food and Beverage | In-kind items and services | $17.98 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/11/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $22.79 | General |
| Category: Cardiology | ||||||
| 10/09/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $13.76 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/09/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $10.75 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/08/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $18.49 | General |
| Category: Cardio-renal | ||||||
| 10/04/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $17.44 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/02/2024 | Medtronic, Inc. | MYCARELINK (Device) | Food and Beverage | In-kind items and services | $36.60 | General |
| Category: Cardiac Diagnostics and Monitoring | ||||||
| 09/25/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $15.07 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 1,079 | 1,901 | $470,981 | $135,913 |
| 2022 | 18 | 1,521 | 2,919 | $818,595 | $226,631 |
| 2021 | 20 | 1,906 | 3,512 | $962,202 | $274,104 |
| 2020 | 31 | 2,600 | 4,074 | $1.1M | $296,701 |
Total Patients
7,106
Total Services
12,406
Medicare Billing
$933,350
Procedure Codes
94
All Medicare Procedures & Services
94 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 341 | 968 | $212,021 | $82,175 | 38.8% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 153 | 161 | $111,829 | $18,470 | 16.5% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 55 | 60 | $37,858 | $7,620 | 20.1% |
| 93925 | Ultrasound of leg arteries or artery grafts | Office | 2023 | 24 | 26 | $19,491 | $4,220 | 21.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 32 | 33 | $11,703 | $3,639 | 31.1% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 64 | 67 | $12,446 | $3,267 | 26.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 63 | 70 | $11,088 | $3,215 | 29.0% |
| 93458 | Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | Facility | 2023 | 14 | 14 | $9,216 | $2,914 | 31.6% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 54 | 64 | $7,363 | $2,664 | 36.2% |
| 93297 | Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | Office | 2023 | 13 | 93 | $7,444 | $1,704 | 22.9% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 28 | 78 | $8,829 | $1,597 | 18.1% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 147 | 148 | $9,728 | $1,303 | 13.4% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 13 | 16 | $3,140 | $874.20 | 27.8% |
| 93922 | Ultrasound study of arm and leg arteries | Office | 2023 | 16 | 16 | $3,210 | $733.52 | 22.9% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Facility | 2023 | 22 | 24 | $2,070 | $632.66 | 30.6% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 15 | 38 | $2,115 | $586.60 | 27.7% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Office | 2023 | 11 | 11 | $858.00 | $200.18 | 23.3% |
| 93246 | Heart rhythm recording of continous external ekg over 8-15 days | Office | 2023 | 14 | 14 | $574.00 | $97.76 | 17.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 368 | 1,136 | $248,949 | $96,537 | 38.8% |
| 99358 | Extended patient service without direct patient contact, first hour | Office | 2022 | 322 | 802 | $262,302 | $63,652 | 24.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 185 | 198 | $137,529 | $24,276 | 17.7% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2022 | 80 | 91 | $57,417 | $12,090 | 21.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 48 | 48 | $17,022 | $5,409 | 31.8% |
| 93925 | Ultrasound of leg arteries or artery grafts | Office | 2022 | 22 | 22 | $16,492 | $3,785 | 23.0% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2022 | 65 | 71 | $13,189 | $3,475 | 26.3% |
About Dr. Riaz Sirajuddin, M.D
Dr. Riaz Sirajuddin, M.D is a Cardiovascular Disease healthcare provider based in Oklahoma City, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1235186099.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Riaz Sirajuddin, M.D has received a total of $483,835 in payments from pharmaceutical and medical device companies, with $37,914 received in 2024. These payments were reported across 1,542 transactions from 50 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($342,232).
As a Medicare-enrolled provider, Sirajuddin has provided services to 7,106 Medicare beneficiaries, totaling 12,406 services with total Medicare billing of $933,350. Data is available for 4 years (2020–2023), covering 94 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Specialist
- Location Oklahoma City, OK
- Active Since 05/27/2006
- Last Updated 05/20/2025
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1235186099
Products in Payments
- Ranexa (Drug) $141,296
- Ozempic (Drug) $115,749
- ZONTIVITY (Drug) $48,057
- NEXLIZET (Drug) $32,505
- XARELTO (Drug) $22,732
- YOSPRALA (Drug) $21,126
- Rybelsus (Drug) $13,655
- PRALUENT ALIROCUMAB INJECTION (Biological) $8,268
- ENTRESTO (Drug) $7,615
- PRALUENT (Drug) $6,467
- Barostim Neo System (Device) $1,751
- Corlanor (Drug) $1,666
- FARXIGA (Drug) $1,265
- Livalo (Drug) $1,154
- ELIQUIS (Drug) $1,048
- BRILINTA (Drug) $889.16
- Repatha (Biological) $827.72
- OPSUMIT (Drug) $616.32
- Kerendia (Drug) $612.34
- Reveal LINQ (Device) $602.58
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Oklahoma City
Warren Jackman, Md, MD
Cardiovascular Disease — Payments: $2.5M
Cardiovascular Disease $2.5M
George Chrysant, Md, MD
Cardiovascular Disease — Payments: $559,592
Cardiovascular Disease $559,592
Sunny Po, Md, MD
Cardiovascular Disease — Payments: $285,383
Cardiovascular Disease $285,383
Dr. John Summers, M.d, M.D
Cardiovascular Disease — Payments: $148,458
Cardiovascular Disease $148,458
Dwight Reynolds, Md, MD
Cardiovascular Disease — Payments: $75,986
Cardiovascular Disease $75,986
Thomas Mcgarry, M.d, M.D
Cardiovascular Disease — Payments: $75,312
Cardiovascular Disease $75,312